First CRISPR therapies for blood disorders approved in 2023 will rank among world's most expensive drugs, costing $3 million per treatment due to complex manufacturing and administration requirements. Current pharmaceutical development system designed for profitable mass-market drugs cannot economically serve rare disease patients, despite having the technology to cure them within 3-5 years.
El País
· Feb 03, 2023
· health
· 7 min de lectura
High
Verificación: Verificado
CRISPR's Promise Meets Market Reality: First Gene-Editing Drugs to Cost $3M
Approximately 300 million people worldwide suffer from rare genetic diseases; many will remain untreated despite available CRISPR technology due to prohibitive costs and lack of market incentives.
◉
Economy & Finance
971 artículos relacionados
Wall Street's AI Rally Echoes 1987 Crash Warning Signs
OkDiario · 99% coincidencia
Wall Street surges on signs of economic cooling, Fed rate-hike pause l…
infobae · 99% coincidencia
Asian stocks fall as Treasury yields hold gains amid inflation concern…
Bloomberg Línea · 99% coincidencia
Inflation Surge Signals Sell for Stock Market Investors as Macro Risks…
Bloomberg Línea · 99% coincidencia
Wall Street hits records ahead of Fed rate cut decision
Diario Las Américas · 99% coincidencia
Cobertura Relacionada
La Vanguardia · Aug 20
China rivaliza con Europa en el 40% de sus industrias clave, alerta Lagarde
China compite directamente con la eurozona en casi el 40% de los sectores donde Europa tiene ventaja comparativa, escala…
AP News · Aug 20 Japón registra récord en importaciones y exportaciones pese a déficit comercialJapón reportó importaciones y exportaciones récord en julio, pero prolongó su déficit comercial por tercer mes consecuti…
Ambito · Aug 20 Wall Street rebota tras caída de rendimientos: Fed mantiene tasas y revela preocupación por inflaciónLos índices de Wall Street cerraron al alza tras la publicación de minutas de la Fed que sugieren mantener tasas de inte…
Ambito · Aug 20 Las reservas del BCRA superan u$s50.000M, pero la acumulación de divisas sigue débilLas reservas brutas del BCRA recuperaron el nivel de USD 50.000 millones impulsadas principalmente por la suba del oro, …
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
CRISPR gene-editing drugs costing €3M per patient will create global health inequities, limiting treatment access to wealthy nations and exacerbating healthcare disparities affecting 300M people with rare genetic diseases.
Escalation Risk
moderate
Confidence
HIGH
United States
European Union
Global South
Middle-income countries
Low-income countries
Wealthy nations and pharmaceutical corporations gain monopolistic control over life-saving genetic therapies, while developing nations face exclusion. This reinforces existing healthcare inequalities and shifts biomedical power toward high-income economies and Big Pharma, potentially triggering international pressure for price regulation and compulsory licensing.
Similar to early antiretroviral HIV/AIDS drug pricing (1990s-2000s), where patent protections and high costs restricted access in developing nations until generic competition and international advocacy forced price reductions. CRISPR pricing may trigger comparable geopolitical tensions over drug accessibility and intellectual property.
Lente Económico
📈
First CRISPR gene-editing drugs priced at €3M per patient create significant access barriers despite technological capability to treat 300M people with rare genetic diseases globally.
Market Signal
mixed
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Health Insurance
Public Health Systems
Medical Devices
Patients with rare genetic diseases face severe affordability barriers despite curative potential. Most households and healthcare systems cannot absorb €3M treatment costs, limiting access to wealthy populations and well-funded healthcare systems. Creates two-tier healthcare outcomes based on economic status.
Governments likely to implement price regulation mechanisms, negotiate bulk purchasing agreements, or mandate insurance coverage frameworks. May trigger patent reform discussions, compulsory licensing debates, and increased public funding for gene therapy research. EU and national health authorities may establish reimbursement criteria and cost-effectiveness thresholds.